Biohybrid templates for peripheral nerve regeneration (BIOHYBRID)

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2011
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
    Peripheral Nerve Dengeneration
  • Location: Europe

Abstract

The overall aim of the BIOHYBRID consortium is the preclinical development of an innovative artificial biohybrid nerve device for the regenerative treatment of traumatic injuries of peripheral nerves.

Mission

With the goal of repairing damaged nerve trunks, the BIOHYBRID consortium will engage in the preclinical development of an innovative artificial biohybrid nerve device for the regenerative treatment of traumatic injuries of peripheral nerves.
 
Based on the extensive basic and clinical experience within this consortium, the artificial nerve device will be developed together with standardized application and evaluation parameters. A key objective of this study is to generate a protocol that serves as a template for future clinical trials in the regenerative therapy of damaged peripheral nerves.

Consortium History

Oct. 2011: Program launched

Structure & Governance

BIOHYBRID consists of three dynamic and reputable Small and Medium-Sized Enterprises (SMEs) as well as seven academic partners that are recognized leaders in the disciplines of neuroanatomy, neuronal regeneration, neurosurgery, and innovative biomaterial research.

The organizational processes of BIOHYBRID ensure timely management to achieve the research objectives within the designated budget and time frame. Organization in these boards enables the efficient and close interaction between the decision-making and the operational management bodies regarding scientific, administrative, and financial aspects of the BIOHYBRID project.

Financing

Funding is provided by the European Commission under the Seventh Framework Programme.

Data Sharing

The results of the multidisciplinary research will feed into the establishment of artificial biohybrid devices as standalone alternatives to accepted standard procedures and tools. Furthermore, standardized application guidelines and evaluation parameters will be set up to enable continuous progress and evaluation of the outcome of clinical application. 

Impact/Accomplishment

BIOHYBRID successfully hosted the one-day First International Workshop on Intrinsic and Extrinsic Mechanisms of Axonal Regeneration on May 27, 2014, in Brussels, Belgium. Leading experts from the field presented the latest insights on the molecular and cellular basis of axonal growth and regeneration. Furthermore, the mid-term achievements of the BIOHYBRID project were presented including the CE approval of the REAXON® Nerve Guide as a first product originating from the initiative. The workshop closed with a round-table discussion about the upcoming first clinical trial using a BIOHYBRID product.

Sponsors & Partners

Participant/Sponsor

Altakitin

Hannover Medical School

Lund University

Medovent

Neural and Vascular Reconstruction Laboratories

Technische Universitat Munchen, Klinikum Rechts der Isar

Tel Aviv Sourasky Medical Center, Tel Aviv University

Universidade do Minho

Universita degli Studi di Torino

Universitat Autonoma de Barcelona


Last Updated: 04/06/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.